The BMF explores the latest developments in research at the ARVO 2016 Congress in Seattle

am16-small_editora_2_119_1

The BMF presented three posters at the annual congress of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle last week. Dr. Jordi Monés spoke about the study “Efficacy of ranibizumab treatment in retinal vein occlusion patients with retinal macular ischemia: 24-month data from BRIGHTER and CRYSTAL”. Meanwhile, Dr. Marc Biarnés explained “Identification of subgroups in geographic atrophy using cluster analysis”, while Míriam Garcia presented “Dark adaptation impairment in patients with drusen.”

20160506 ARVO muntatge opt

 

Apart from disseminating the research conducted by the Foundation, Dr. Monés was very busy with knowledge exchanges with experts from around the world and his roles on the international Advisory Boards of a variety of pharmaceutical companies attending the Congress.

This annual event draws over 11,000 experts in top-notch ophthalmological research in order to explore the latest developments in basic and clinical research.

Among the key aspects examined at the Congress was the development of OCT (optical coherence tomography) angiography, a new non-invasive technique generating volumetric images that incorporate structural and blood-flow information in a matter of seconds. ARVO 2016 provided the opportunity to share and compare expert points of view on the benefits and limitations of using this new technology.

The BMF delegation also studied the variants in the development of adaptive optics, which is used to study the retina’s structure and function in healthy patients and those with pathology. 

Research is the only solution for the future to fight against blindness

It is only with your help that we can fight against blindness

Collaborate